Rabbit Anti-Human APP/Beta Amyloid 43 pAb

No significant cross-reactivity of Aa40 or Aa42 has been observed.

Rabbit polyclonal immunoglobulins in phosphate buffer, pH 7.4. Carrier and preservative free.

Alzheimer’s Disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major component of these plaques is Aa peptide (a-amyloid), a 40 to 43 amino acid peptide cleaved from amyloid precursor protein (APP). Increased release of the ‘longer forms’ of Aa peptide, Aa42 or Aa43, which have a greater tendency to aggregate than Aa40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alleles, or may involve other, still undiscovered, factors. Many researchers theorize that this increased release of Aa42/Aa43 leads to the abnormal deposition of Aa and the associated neurotoxicity in the brains of affected individuals.